Stenocare Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Thomas Schnegelsberg

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7.1yrs
CEO ownership	n/a
Management average tenure	7.1yrs
Board average tenure	6.2yrs

Recent management updates

Recent updates

CEO

Thomas Schnegelsberg (59 yo)

7.1yrs

Tenure

Mr. Thomas Skovlund Schnegelsberg serves as Chief Executive Officer since October 2017 and Co-Founder of Stenocare A/S. Mr. Schnegelsberg serves as Deputy Chairman of Bagsværd Kost- & Gymnasium Skole. Mr....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Schnegelsberg	CEO, Co-Founder & Member of Executive Board	7.1yrs	no data	no data
Rolf Petersen	Co-Founder & Chief Commercial Officer	no data	no data	8.37% DKK 3.7m
Soren Kjaer	Co-Founder & COO	7.8yrs	no data	no data
Peter Johansen	Chief Financial Officer	6.3yrs	no data	no data

7.1yrs

Average Tenure

59.5yo

Average Age

Experienced Management: STENO's management team is seasoned and experienced (7.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jeppe Petersen	Independent Director	6.2yrs	no data	no data
Marianne Wier	Non Executive Independent Chairman	6.2yrs	no data	no data
Soren Frederiksen	Independent Director	6.2yrs	no data	no data

6.2yrs

Average Tenure

58yo

Average Age

Experienced Board: STENO's board of directors are considered experienced (6.2 years average tenure).

Stenocare Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Stenocare A/S Announces Resignation of Søren Kjær as Board Member

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Insufficient new directors

Third quarter 2024 earnings released

Stenocare A/S to Report Q1, 2025 Results on May 08, 2025

Stenocare A/S Announces Resignation of Søren Kjær as Board Member

Stenocare A/S Updates Earnings Guidance for the Year 2024

Second quarter 2024 earnings released

Stenocare A/S Updates Sales Guidance for the Year 2024

Stenocare A/S Launches Next Generation Medical Cannabis Oil Product in Australia

First quarter 2024 earnings released

Stenocare A/S to Report Fiscal Year 2024 Results on Feb 27, 2025

Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in Denmark

Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian Patients

New major risk - Share price stability

STENOCARE Receives Approval to Sell a New Medical Cannabis Oil Product in Denmark

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.1.40 loss in FY 2022)

Stenocare A/S to Report Q1, 2024 Results on May 02, 2024

New major risk - Shareholder dilution

Stenocare A/S Expands Presence with New Medical Cannabis Oil Product

Third quarter 2023 earnings released

Stenocare Ready to Ship Medical Cannabis to German Patients

Second quarter 2023 earnings released

Stenocare A/S Provides Sales Guidance for the Year 2023

Stenocare A/S Provides Update on Their Strong Danish Product Pipeline

First quarter 2023 earnings released

New minor risk - Shareholder dilution

Stenocare A/S Reports on Significant Progress in Development of Its New Innovative Medical Cannabis Product

Stenocare A/S Launches IT-Platform for Online Clinics

Full year 2022 earnings released

Stenocare A/S Provides Sales Guidance for the Year 2023

Stenocare's New STENOCARE CBD Medical Cannabis Oil Product Is Available in Denmark

Less than half of directors are independent

Stenocare A/S Reaffirms Sales Guidance for the Fourth Quarter of 2022 and Provides Sales Guidance for the Year 2023

Third quarter 2022 earnings released

Stenocare A/S Receives Approval from the Danish Medicines Agency to Sell New Cbd Medical Cannabis Oil Product to Danish Patients

Stenocare A/S Announces Results from New Medical Cannabis Oil Study

Second quarter 2022 earnings released

First quarter 2022 earnings released

Less than half of directors are independent

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

Stenocare A/S and Solural Pharma Announce Positive Outcome of Feasibility Study

Stenocare A/S Approves to Supply Danish Patients with Medical Cannabis Oil Products

We're Keeping An Eye On Stenocare's (CPH:STENO) Cash Burn Rate

First quarter 2021 earnings released

Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?

More Choice for Treatment of Swedish Patients with Medical Cannabis Oil

Emerald Health Therapeutics, Inc. Announces That Its Partner, Stenocare A/S, Completed Its First Shipment and Delivery of Emerald Medical Cannabis Oil

STENOCARE A/S and Emerald Health Therapeutics Inc Announces First Shipment and Delivery of Medical Cannabis Oil

New 90-day high: kr.18.24

Is Stenocare (CPH:STENO) In A Good Position To Invest In Growth?

Stenocare A/S to Report Q1, 2021 Results on May 06, 2021

Stenocare A/S to Report Q2, 2021 Results on Aug 19, 2021

New 90-day low: kr.15.16

New 90-day low: kr.16.30

Stenocare A/S (Denmark) to Be from Other OTC

Stenocare A/S to Report Fiscal Year 2020 Results on Feb 25, 2021

Earnings released

Stenocare A/S to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low - kr.17.06

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age